LB Pharmaceuticals Inc (LBRX)

LB Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Selling, General & Admin	15.83	13.66	3.53	1.46
Research & Development	16.38	51.17	7.85	1.35
Operating Expenses	32.21	64.83	11.38	2.81
Operating Income	-32.21	-64.83	-11.38	-2.81
Interest Expense	-	-	-4.83	-2.15
Interest & Investment Income	1.1	1.72	0.81	0.07
Other Non Operating Income (Expenses)	1.4	-0.95	16.22	-9.46
EBT Excluding Unusual Items	-29.71	-64.06	0.83	-14.35
Gain (Loss) on Sale of Investments	0.98	0.96	0.33	0
Other Unusual Items	-	-	-7.44	-
Pretax Income	-29.43	-63.1	-6.27	-14.35
Income Tax Expense	0	0	0	0
Net Income	-29.43	-63.1	-6.28	-14.35
Net Income to Common	-29.43	-63.1	-6.28	-14.35
Shares Outstanding (Basic)	0	0	0	0
Shares Outstanding (Diluted)	0	0	0	0
Shares Change (YoY)	0.87%	0.87%	8.02%	-
EPS (Basic)	-116.88	-250.61	-25.14	-62.09
EPS (Diluted)	-116.88	-250.61	-25.14	-62.09
Free Cash Flow	-42.13	-53.82	-12.12	-2.73
Free Cash Flow Per Share	-167.31	-213.75	-48.55	-11.80
EBITDA	-31.97	-64.74	-11.37	-2.81
D&A For EBITDA	0.24	0.09	0	0
EBIT	-32.21	-64.83	-11.38	-2.81

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q